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Breast cancer is by far the most common cancer in women.
Despite progress in surgical techniques and treatment, many
patients will relapse (Nemoto et al, 1980). For patients without
evidence of systemic dissemination after primary surgery, prog-
nostic parameters such as tumour size, nodal status, grading,
hormonal receptor expression and others are determined. Using
these parameters a statistical assessment of the risk of relapse
leads to the decision whether to give systemic adjuvant
chemotherapy or not. Undetected disseminated cancer cells can
contribute to the failure of primary treatment. Moreover, the
success of different therapeutic regimes is limited, as even cancer
therapy is not always able to completely eradicate all neoplastic
cells disseminated from the primary tumour. Therefore, detection
of remaining minimal residual disease in individual patients could
have an important clinical impact on assessment of prognosis and
therapy outcome for breast cancer patients. 
Genesis of a sporadic tumour is a multistage process involving
activation of oncogenes and inactivation of tumour-suppressor
genes (Lizard Nacol et al, 1997). Some tumour cells invade and
generate metastases via either lymphatic or blood vessels. After
primary resection surgery minimal residual cancer cells (MRCC)
are the actual targets for chemotherapeutic drugs. Until now
several attempts have been made to detect or isolate disseminated
tumour cells from peripheral blood or bone marrow (Nawroz et al,
1996; Denis et al, 1997; Brandt et al, 1998; Leitzel et al, 1998;
Naume et al, 1998; Soria et al, 1999). In nearly all analytical
approaches, RT-PCR analyses were used to detect micro-
metastatic, disseminated cancer cells. Contrasting to the analysis
of RNA, determination of genomic imbalances (GI) using DNA
needs extremely pure cancer cells. Therefore, we established a
new density and size-dependent method to isolate MRCC from
blood. The method is based on observations that extravasation of
tumour cells often occurs in clusters of malignant cells and clot-
ting in the blood appears by aggregation of tumour cells and
thrombocytes leading to the formation of large particles (Friedl 
et al, 1995; Aigner et al, 1997; Brandt et al, 1998). Furthermore,
aggregated tumour cells in circulation may be a result of released,
formally endothelial-attached micrometastases (Al-Mehdi et al,
2000). Identification and characterization of purified disseminated
tumour cells in our approach is based on the analysis of genomic
DNA. By this we exclude any problems of RT-PCR assays
resulting from basal transcription of so called ‘tumour-specific’
and ‘tumour-associated’ genes of normal cells avoiding false pos-
itive findings (Lopez Guerrero et al, 1997; Zippelius et al, 1997).
To determine tumour cells we measured genomic imbalances (GI)
of 15 different genes; 13 tumour suppressor genes and 2 onco-
genes. Once a tumour suppressor gene is inactivated on one allele
loss of heterozygosity may uncover a phenotypic recessive muta-
tional event in the remaining allele (Heide et al, 1997), a process
which often occurs in early tumorigenesis. In the present study, we
applied PCR-based detection of GI in archived DNA derived from
isolated MRCC of 353 breast cancer patients. The prognostic re-
levance of MRCC with respect to the number and kind of genomic
imbalances was subsequently evaluated. 
MATERIALS AND METHODS 
Patients and tumour characteristics 
Since 1993 we have analysed disseminated tumour cells in blood
and bone marrow of mainly breast and colon cancer patients. After
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hospitals and specialized oncological hospitals, the patients
follow-up was done by specialized oncologists. Blood samples
were provided by several oncological centres of excellency in an
open-cohort study. Detailed patients data (diagnosis, histology,
treatment regiments, clinical follow-up data) were provided by a
questionnaire. 
For long-term storage of patients samples, we established a
central archive for nucleic acids and proteins (CANAP) (Figure 1).
This archive contains serum samples, purified RNA, DNA and
proteins from isolated CD45 positive lymphocytes, MNCs and
separated MRCC from patients with different malignant disorders.
Using this archive as well as a yearly updated clinical database, 
we are able to analyse different parameters of interest by e.g. PCR
analyses. 
In the following investigation, DNA-samples stored in CANAP
extracted from separated MRCC fractions and matched control cells
from 860 patients with histologically proven, primary breast cancer
diagnosed between 1983 and 1998 were analysed. Clinical follow-
up including all medical data are completed for 596 patients. An
observation time of at least 100 months after the time of first diag-
nosis is available for 353 patients. Patients with previous diagnosis
of other malignant disorders as well as breast cancer patients with
distant metastases at the time of first diagnosis were excluded. None
of the patients received neo-adjuvant treatment before primary
surgery. The median number of lymph nodes removed surgically
was 18 (min 2; max 46). Median age of the patients (first diagnosis)
was 51 years (range 25–85 years). Radiotherapy was given to 53%
of the patients. 25% and 69% of the node-negative or -positive
patients received adjuvant chemotherapy, respectively. 59% of all
patients received hormonal therapy, either alone (34%) or in com-
bination with chemotherapy (23%). During the observation time,
158/353 (44.7%) patients relapsed. 
Further characteristics of patients and tumours are listed in
Table 1. Blood samples derived from 24 apparently healthy female
volunteers of our laboratory staff were used in control experi-
ments. The patients participating in this study gave their informed
consent for all analyses presented in this report. 
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Central Archive for Nucleic Acids
and Proteins (CANAP)
Plasma
storage: -80￿C 12.2 ml Blood
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mononucleated
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0.2 ml MNC
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for MRCC separation
CD45
+ separation
as wt-control
Isolation of RNA, DNA and proteins using TRIzol;
storage under ethanol (-80￿C)
DNA (MRCC) DNA (wt-control)
Examination of genomic imbalances
like LOH, mutation and amplification
using capillary electrophoresis
Figure 1 Schematic diagram of blood fractionation and storage in the
central archive of nucleic acids and proteins (CANAP) as described in
Materials and methods 
Table 1 Patients characteristics 
State No relapse Relapse within first 2 years Relapse 2–5 years after  Relapse more than  
after primary diagnosis primary diagnosis 5 years after first diagnosis
Nodal state 
N  (n, 146) 92 (63%) 26 (18%) 19 (13%) 9 (6%) 
N+ (n, 161) 82 (51%) 37 (23%) 30 (19%) 12 (7%) 
unknown (n, 46) 21 (46%) 8 (17%) 11 (24%) 6 (13%) 
Tumour size 
Tis (n, 5) 3 (60%) 1 (20%) 1 (20%) 0 (0%) 
T1 (n, 125) 85 (68%) 17 (14%) 16 (13%) 7 (6%) 
T2 (n, 156) 78 (50%) 37 (24%) 28 (18%) 13 (8%) 
T3/4 (n, 30) 13 (43%) 9 (30%) 7 (23%) 1 (3%) 
unknown (n, 37) 16 (43%) 7 (19%) 8 (22%) 6 (16%) 
Grading 
G1 (n, 17) 10 (59%) 3 (18%) 3 (18%) 1 (6%) 
G2 (n, 136) 79 (58%) 27 (20%) 16 (12%) 14 (10%) 
G3–4 (n, 112) 59 (53%) 23 (21%) 27 (24%) 3 (3%) 
unknown (n, 88) 47 (53%) 18 (20%) 14 (16%) 9 (10%) 
Menopausal 
pre (n, 113) 51 (45%) 30 (27%) 20 (18%) 12 (11%) 
post (n, 182) 111 (61%) 31 (17%) 28 (15%) 12 (7%) 
unknown (n, 58) 33 (57%) 10 (17%) 12 (21%) 3 (5%) 
Clinical, pathological and biological status of 353 breast carcinoma patients stratified for nodal state (N), tumour size (T), grading (G) or menopausal state and
time to relapse. Isolation of minimal residual cancer cells (MRCC) and
patient’s matched control cells (Figure 1) 
Peripheral blood was collected in heparinized Vacutainer systems
(Becton Dickinson). Mononucleated cells (MNC) from 12.2 ml
peripheral blood were purified over a density gradient using
Nycoprep 1.077 (Nycomed, Norway). Collected MNC-fractions
were washed twice with PBS (0.2% BSA; Life Technologies,
Germany) and resuspended finally in 12.2 ml PBS (0.2% BSA).
Cells derived from 5 ml of the MNC suspension were lysed 
in Trizol (Life Technologies, Germany) for archiving untouched
material. 7 ml of the purified MNCs were used for sub-
sequent isolation of MRCC. The cell suspension was separated by 
size using a column containing a polyester mesh (mesh-opening 
20 µ m; RELABAG, Germany). After separation of the MNC
suspension the mesh was rinsed 10 times using 5 ml PBS each.
After washing, the cells retained on the mesh were lysed using
Trizol (Life Technologies, Germany). Patient’s matched CD45
positive lymphocytes were isolated from 0.2 ml of the MNC
fraction using anti-CD45 mAb coated magnetic beads (Dynal,
Norway) and lysed using Trizol. DNA and RNA of control cells
and MRCC were extracted according to the manufacturer’s
instructions. Isolated DNA derived from MRCC fraction and from
patients matched control lymphocytes were used to determine GI. 
Spiking and recovery of carcinoma cells 
In spiking experiments, we used the SW480 colon carcinoma cell
line SW480 because of its known Ki-rascodon 12 mutation (GGT
(Gly) → GTT (Val)). SW480 tumour cells were grown for 24–48
hours either in silanized glass tubes leading to cellular aggregation
or in normal tissue flasks using DMEM, 10% FCS as culture
medium. Silanization of glassware was done using 1 ml/tube 
0.5% Dimethyldichlorsilane in toluene (FLUKA, Germany). Glass
tubes were incubated for 20 min and washed 3 times using 
1.5 ml toluene each. Glass tubes were washed again using 1.5 ml
methanol and finally using 5 ml 70% ethanol. Cells were harvested
from tissue flasks using trypsin/EDTA solution (GibcoBRL,
Germany) and washed twice (400 g, 4˚C, 5 min) with PBS (0.2%
FCS) leading in the majority to single cells. Cells from silanized
glass tubes were transferred into a new glass tube and washed
twice (400 g, 4˚C, 1 min) with PBS (0.2% FCS). Cells were
counted (an aliquot of clustered cells was previously trypsinized)
using trypan blue exclusion. SW480 cells were spiked in 5 ml
whole blood or in previously isolated peripheral blood mono-
nuclear cells (MNC) derived from 5 ml heparinized blood as
described. Reisolation of the spiked carcinoma cells and nucleic
acid preparation of the resulting fractions was done as described
above (Isolation of MRCC). The experiment was repeated three
times. Analysis of Ki-rascodon 12 mutation and DCC-LOH was
performed as described below. 
Analysis of 17-1A (EGP) expression 
Analysis of 17-1A expression was done using RT-PCR. Briefly,
RNA was isolated using Trizol and reversely transcribed using
random-hexameres according to a standard protocol. The resulting
cDNA was amplified using the following conditions: 
EGP-1: 5′ -6FAM-CGT CAA TGC CAG TGT ACT TC-3′
EGP-2: 5′ -AAC GCG TTG TGA TCT CCT TC-3′
95˚C, 10 min/38 × (94˚C, 30s; 58˚C, 30s; 72˚C, 30s)/72˚C,
5 min. 
The resulting FAM-labelled PCR product (390 bp) was analysed
using capillary gel electrophoresis (Genescan genetic analyser 310
(AbiPrism, Perkin Elmer)). 
Analysis of genomic imbalances 
Ki-rascodon 12 mutuation and p53hot-spot mutations were
analysed using PCR with subsequent mutation-specific restriction
of the PCR product (Chen et al, 1993; Hardingham et al, 1993).
Quantification of the restricted PCR products was done using
capillary gel electrophoresis (Genescan genetic analyser 310
(AbiPrism, Perkin Elmer)). 
Patterns of allelic losses and amplified oncogenes were
measured for p53(TP53), RB-1(exon 20), DCCand APC(McGee
et al, 1989; van Leeuwen et al, 1991; Huang et al, 1992; Cawkwell
et al, 1994; Kirchweger et al, 1994; Cho et al, 1996; Crundwell et
al, 1996). Furthermore, GI were detected using the follow-
ing microsatellite specific primers; D17S926 (AFM207xa11),
D17S695 (nm00089), D17S849 (AFM234wg3), D17S960 (AFMa-
120xd5),D16S265 (D16S265.PCR1), D16S496 (AFM214ZG5)
and D11S528 (42026/27) (Hauge et al, 1991; Carter et al, 1994;
Gyapay et al, 1994) and p16on regions D9S126 (D9S126.
PCR1) and D9S171 (AFM126xc3) (Liggett and Sidransky, 1998;
Villuendas et al, 1998). Amplification of oncogenes was measured
using a multiplex PCR using primer sequences specific for 
c-erbB-2or c-myccoamplified with β -globin, distinguishable both
by fluorescence label and size. Sense primers were labelled 
with fluorogenic molecules 6-FAM or HEX (TIBMOLBIOL,
Germany). Briefly, DNA-PCR products resulting from CD45 posi-
tive lymphocytes (wild-type control) were compared with the PCR
profile generated from the isolated MRCC-fraction. Resulting
products were analysed by capillary gel electrophoresis (Genescan
genetic analyser 310; AbiPrism, Perkin Elmer). All PCR parame-
ters were optimized for reliable amplification and fluorogenic
detection (further information can be requested from the authors).
To determine loss of heterozygosity allele ratios were calculated as
described (Cawkwell et al, 1993) with minor alterations. Briefly,
the size of both alleles for heterozygous (informative) patients was
assigned according to both peaks of greatest integral in the patients
CD45 positive control sample. The peak integrals of the two
alleles in the paired normal and tumour sample were used to deter-
mine genomic imbalance (GI) using a relative allelic difference of
50% as a cut-off value. Furthermore, the presence of LOH was
accepted as positive only, if the integral of the resulting
microsatellite peak was ≥ 2000 and the peak/noise ratio was ≥ 50. 
In case of amplified oncogenes c-mycand c-erbB-2GI was
calculated by the value of the peak area derived from the analysed
oncogene compared with the integral of the β -globin peak:
OT:GT/ON:GN, where OT and ON are the integrals of the
oncogene peak areas and GT and GN the peak area values of β -
globin for the tumour (T) and CD45 control sample (N). Genomic
imbalance (amplification) was given if the resulting ratio was
greater than or equal 2.00. Furthermore, the presence of an ampli-
fication was accepted as positive only, if the integral of the
resulting PCR-product peak was ≥ 2000 and the peak/noise ratio
was ≥ 50. 
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To compare the frequencies of categorical variables between two
groups the Chi-Square test was used, with P < 0.05 considered as
statistically significant. The relationship between the dependent
variable ‘genomic imbalance’ of DNA and the independent vari-
ables nodal status, menopausal status and grading was assessed by
use of a logistic regression. Relapse-free survival interval (RFS)
was defined as the period between date of first diagnosis of 
breast cancer and documented relapse. Patients without an event
were censored. Survival curves were drawn with the use of
Kaplan–Meier product limit method. The log-rank test was used to
compare two or more survival distributions. Multivariate analyses
were performed using the Cox proportional hazards model, P
values were derived from Wald’s Chi-Square test. To the basic
multivariate model, which included nodal status, menopausal
status and grading, the variable ‘genomic imbalances’ of DNA
was added. The important prognostic factors were identified by
use of the stepwise selection method. All computations were
performed using the SAS software package, release 6.12. 
RESULTS 
Spiking and recovery of carcinoma cells 
The proof of principle of cancer cell separation by size was
performed using the colon carcinoma cell line SW480 because of
its known Ki-ras codon 12 mutation. Recovery and purity of the
re-isolated tumour cells after spiking of single and aggregated
SW480 carcinoma cells in previously isolated mononuclear cells
was determined (Table 2). The majority of aggregated cells gener-
ated after growing them for 24 hours in silanized glass tubes
showed clusters consisting of 5 to 15 cells 30–70  µ m in size
(Figure 2B). In contrast, the majority of trypsinized SW480 cells
consisted of single cells with 16.5 µ m in diameter (Figure 2A).
Purity and recovery of spiked and reisolated SW480 single and
clustered cells was determined by the analysis of Ki-ras codon 
12 mutation using a restriction-fragment-length-polymorphism
analysis (RFLP). Using this kind of analysis, a fragment of 114 bp
is indicative for wild-type Ki-ras codon 12, whereas a product of
143 bp resembles a mutated Ki-ras codon 12. Analysing the two
peak integrals resulting from capillary electrophoresis, one is able
to determine the relative distribution of mutated vs wild-type frag-
ments. Whereas the mean recovery of clustered cells varied be-
tween 54% and 68%, the mean purity was generally higher than
50%. In case of single cells positive results could not be obtained. 
Amplification of 17-1A specific RNA from isolated aggregated
SW480 cancer cells showed strong positive signals, but only a
weak signal in the isolated fraction when 1500 single cells were
spiked. In parallel, microsatellite analysis of the DCC tumour
suppressor gene revealed reliable detection of ‘LOH’ after spiking
and isolation of 30 aggregated SW480 cells (data not shown). 
Genomic imbalances in minimal residual cancer cells
isolated from blood of breast cancer patients 
In MRCC fractions derived from 353 breast cancer patients (Table 1)
and 24 healthy volunteers we analysed the following genes and
chromosomal regions: amplification of c-erbB-2 and c-myc, p53-
mutations (5 hot-spot mutations) and LOH of p53, DCC, RB-1,
APC, D9S126, D9S171, D16S496 and D17S695. Using this panel
of analyses, we neither found GI of either tumour suppressor genes
nor proto-oncogenes in MRCC fractions derived from 24 healthy
volunteers (data not shown). In breast cancer patients (n = 353) we
found MRCC with several GI in different genes and chromosomal
regions. When these patients were stratified into 4 groups with
respect to GI of the DCC and c-erbB-2 gene (Figure 3; I, III, IV
and V), amplification of the proto-oncogene c-erbB-2 and LOH of
the DCC gene showed a clear and significant correlation with a
worse RFS (I vs III: P = 0.006; I vs V: P = 0.0004). These differ-
ences were also significant if compared with the actuarial RFS of
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Table 2 Reisolation of spiked carcinoma cells 
Analysis of Ki-ras Codon 12 mutationa
17-1Ad
Number of spiked cells Integral 114 bp (wt) Integral 143bp (mt) Recoveryb (%) Purityc (%) Integral 390 bp 
agg 1500 8410 ± 2741 23322 ± 7054 64 ± 12 73 ± 5 19846 ± 2106 
agg 300 2730 ± 1996 6981 ± 2580 57 ± 9 75 ± 16 7798 ± 1142 
agg 150 2969 ± 2586 4760 ± 2010 68 ± 13 66 ± 13 5276 ± 1327 
agg 30 1480 ± 1083 1562 ± 1504 54 ± 17 50 ± 14 3609 ± 953 
0 1583 ± 456 nd –– nd 
sin 1500 7309 ± 1634 nd nd nd 547 ± 340 
sin 300 4031 ± 882 nd nd nd nd 
sin 150 2192 ± 896 nd nd nd nd 
sin 30 5003 ± 3700 nd nd nd nd 
0 3197 ± 2927 nd –– nd 
Input control 
1500 SW480 nd 39769 ± 15635 – 100 
300 SW480 nd 13240 ± 5553 – 100 
150 SW480 nd 6534 ± 2224 – 100 
30 SW480 nd 2324 ± 1641 – 100 
Aggregated (agg) and single (sin) SW480 colon-carcinoma cells were spiked in MNCs derived from 5 ml heparinized blood from healthy volunteers and
reisolated by size as described. The values correspond to the average ± standard deviation of the peak integrals of the PCR-products derived from 3
independent experiments. aKi-ras codon 12 mutation was analysed by PCR with subsequent mutation-specific restriction of the PCR product as described in
Materials and methods leading to a 114 bp fragment (wild-type) or to a 143 bp fragment (mutated). bRecovery was calculated using the integral of the SW480
input control as 100%. 
cPurity was calculated by addition of both peak integrals (114 bp + 143 bp) = 100%. dThe expression of the 17-1A (EGP) antigen was semiquantitatively
measured using a RT-PCR system as described. nd: not detected; sin: single cells; agg: aggregated cells. 1668 F Austrup et al
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unstratified (all) patients (Figure 3, IV vs II; P= 0.014). Figure 4
shows the actuarial RFS curves of patients as a function of GI (14
parameters) (A), nodal status (B) and grading (C). Clearly, patients
with ≥ 2 detectable GI in MRCC (Figure 4A) experienced a very
poor prognosis. We found a clear and significant correlation
comparing the number of GI detected in MRCC and the actuarial
RFS (all patients vs ≥ 2 GI: P= 0.026; 0 GI vs ≥ 2 GI: P= 0.0008).
In turn, patients with no detectable GI in the MRCC fraction
encountered a favourable prognosis (0 GI vs all: P= 0.021).
Analysing RFS as a function of nodal status or grading (Figure 4
B,C), significant differences were found only between nodal nega-
tive and positive patients (P= 0.026). In Figure 5 we plotted the
actuarial RFS of nodal negative and nodal positive patients as a
function of GI (14 parameters) in MRCC. When dividing nodal
negative patients into two groups by the number of GI identified in
MRCC (I, 0–1 GI and III, ≥ 2 GI), increasing numbers of GI were
significantly correlated with poor prognosis of an ongoing disease
(0–1 GI vs ≥ 2 GI: P= 0.001). In nodal positive patients (Figure 5B)
we also found a clear correlation of the number of GI in MRCC and
worse RFS (0–1 GI vs ≥ 2 GI: P= 0.001; all patients vs ≥ 2 GI: P=
0.016). On the other hand, we found an improved RFS associated
with lower numbers of GI (especially negative for MRCC if no GI
was detected) in MRCC (0–1 GI vs all patients: P= 0.034). 
Analysing the actuarial RFS in all patients without adjuvant
chemotherapy (Figure 6A; n= 178), we also found a clear and
significant correlation comparing the number of GI detected in
MRCC and the actuarial RFS (0–1 GI vs ≥ 2 GI; P= 0.006). In
nodal negative patients analysed before adjuvant chemotherapy 
(n= 92 from 596) for GI in MRCC we found in 23% more than or
equal 2 GI (Figure 6B). On the other hand, 77% of these patients
tested were either negative (33%) or positive for only one GI
(44%) in separated MRCC. 
Analysing MRCC isolated from N0M0 patients, we found 0, 1
and ≥ 2 GI in 21.8%, 43.6% and 34.5% of the patients samples,
respectively. Whereas 16% of the patients without detectable GI in
isolated MRCC relapsed, 55% of the patients with ≥ 2 GI showed
an ongoing disease (P= 0.003) (Figure 6C, n= 110). To clearly
verify that increasing numbers of GI detected in disseminated
cancer cells of patients correlates with worse prognosis of clinical
outcome, we re-analysed 6 additionally GI in separated MRCC
derived from blood of 199, randomly selected patients (Figure 7;
20 parameters; resulting from 353 patients with complete medical
  SW480 single cells B: SW480 aggregated cells
50 m m 50 m m
Figure 2 Comparison of aggregated vs not aggregated SW480 carcinoma cells. Cells were grown for 24–48 hours in tissue flasks (RPMI/FCS) and harvested
using trypsin/EDTA leading in a majority to single cells (A). For aggregation the cells were grown in silanized glass tubes and harvested after 24–48 hours of
incubation (B). The majority of cells formed aggregates ranging from 5 to 15 cells. The bar represents 50 µ m 
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Figure 3 Actuarial relapse-free survival curves for breast cancer patients
stratified by genomic imbalances of c-erbB-2and DCCin isolated MRCC.
MRCC fractions from all patients (n= 353; II: RFS for all, unstratified
patients) were analysed. Patients tested positive for c-erbB-2amplification
(III), DCC-LOH (V) and positive for GI of c-erbB2or DCC(IV) were given.
Patients tested negative (I) were included only, if the analysis was informative
(heterozygous; 60%) for DCCand evaluable (peak-integrals of the measured
PCR-products) for c-erbB-2and DCCanalyses as described in the Materials
and methods section. Numbers between brackets: failures/total number of
patients in each group. Statistical analyses are shown in the box files and full observation time). In control samples, no GI could 
be detected using these marker panel (data not shown). Again,
patients without detectable GI in the MRCC fraction were used in
calculations only, if the DCC marker was informative and analysis
of DCC and c-erbB-2 was reliable, leading to 183 patients analys-
ed for actuarial RFS. In accordance with our previous results, we
found a clear correlation between increasing numbers of GI
measured in MRCC and worse RFS. There was a tendency, not a
statistically significant difference, comparing actuarial RFS of
patients without detectable GI in MRCC and patients with 1 GI in
isolated cancer cells. Comparing patients with no detectable GI in
MRCC and patients with 2–3 GI or ≥ 4 GI in disseminated cancer
cells, we found again highly significant statistical differences in
RFS with P = 0.004 and P = 0.002, respectively. 
The quantity of GI in MRCC of 183 patients evaluable for
analysis of relapse-free survival ranged from 1 to 7. In logistic
regression (Table 3A) including GI, nodal status, grading and
menopausal status, we found GI as an independent factor (P value
ranged from 0.40–0.73). Cox multivariate regression analysis was
performed to compare the prognostic significance of GI in MRCC
with that of the classical prognostic parameters (Table 3B), these
latter variables comprising a basic multivariate model. Corrected
for the basic multivariate model, GI in MRCC were highly related
with a poor RFS (P = 0.002). 
DISCUSSION 
In addition to the classical prognostic factors for patients with
breast cancer, it would be beneficial to have tools available, which
could independently predict the recurrence of disease of individual
patients, define possible drug targets and to follow up the efficacy
of response to systemic therapy. Consequently many research
groups have done considerable work to detect or isolate dissemin-
ated cancer cells. In most cases, the isolation procedures based on
immunological methods. Paramagnetic beads conjugated with
monoclonal antibodies were used to capture disseminated (epi-
thelial) cells (Brandt et al, 1998; Soria et al, 1999). Major limita-
tions of immunomagnetic isolation protocols are altered or masked
antigenic epitopes and down-regulation of antigen expression.
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Figure 4 Actuarial relapse-free survival curves for breast cancer patients
stratified by genomic imbalances detected in isolated MRCC of the blood (A),
nodal status (B) and grading (C). The following genes and chromosomal
regions were analysed (14 parameters: c-erbB-2 and c-myc amplification,
p53-mutation (codon 175, 245, 248, 249, 273), DCC-, RB-1-, APC-, p53-,
D9S126, D9S171, and D17S695). In plot A, MRCC from all patients (n = 353,
thick line: RFS for all, unstratified patients) were analysed. Patients tested
positive for genomic imbalances were included as indicated (1 GI and ≥ 2 GI).
Patients tested negative for GI in MRCC were included only if the analysis
was informative (heterozygous) for DCC and evaluable (peak-integrals of the
measured PCR-products) in c-erbB-2 and DCC analyses as described in the
Materials and methods section. Numbers between brackets: failures/total
number of patients in each group. Statistical analyses are shown in the box 
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Figure 5 Actuarial relapse-free survival curves for breast cancer patients
stratified by genomic imbalances (14 parameters; see Figure 4) detected in
isolated MRCC of the blood derived from nodal-negative (A; n = 146) and
nodal-positive (B; n = 161) patients. Patients tested positive for genomic
imbalances in isolated MRCC were included as indicated (1 GI and ≥ 2 GI).
Patients tested negative for GI in MRCC were included only if the analysis
was informative (heterozygous) for DCC and evaluable (peak-integrals of the
measured PCR-products) in c-erbB-2 and DCC analyses as described in the
Materials and methods section. Line II: RFS for all, unstratified patients within
this group. Numbers between brackets: failures/total number of patients in
each group. Statistical analyses are shown in the box Furthermore, the basal transcription of epithelial specific antigens
in normal blood cells (de Graaf et al, 1997) may affect the purity of
isolated tumour cells. 
We developed a novel technique designed for a continuous
monitoring of cancer management in individual patients. In
contrast to antigen-dependent purification, cells larger than 20 µ m
and cancer cell aggregates, eventually micrometastases, were
isolated through a filtration process. Because the outcome of this
procedure is susceptible for aggregated normal cells, we optimized
our isolation protocol preventing passive aggregation. The first
and crucial step in density and size dependent MRCC purification
is blood collection and isolation of MNCs using a density gradient
centrifugation. Normally, blood samples are collected in plastic
syringes containing anticoagulants, systems which are in general
susceptible for micro-agglutination. Furthermore, isolation of
MNCs is often performed using density media based on Ficoll.
These synthetic polysaccharides lead to an aggregation of red
blood cells and possibly to a clotting of rare cells with or within
the aggregated blood cells. To overcome these problems of passive
aggregation we used heparinized glass vacutainer systems for
blood collection. Furthermore, the density medium NycoPrep does
not contain polysaccharides thus preventing the generation of ag-
gregates during MNC isolation. Using these modifications, MNC
fractions without visible aggregates could be obtained. 
To prove the principle of our isolation system, we used MNCs
of healthy donors spiked with aggregated or single SW480 colon
carcinoma cells (Figure 2 and Table 2). SW480 colon carcinoma
cells were used because of the known Ki-rascodon 12 mutation
which is readily detectable by PCR with subsequent mutation-
specific restriction of the PCR product. In first experiments we
spiked single and clustered tumour cells in whole blood of healthy
volunteers. Despite good recovery of the spiked SW480 cells
using size-dependent separation, the purity was generally lower
than 50%. Further analyses of the isolated cells using cytospins
and FACS showed tumour cells aggregated with CD45+ blood
lymphocytes (data not shown). This can be explained by the allo-
geneic differences of the spiked SW480 cells and donor lympho-
cytes, circumstances not given in real patient samples. Therefore,
to reduce the time leading to lymphocyte–tumour cell interactions
we used previously isolated MNC from healthy volunteers in
reisolation experiments. Using a simple but effective filtration
process it could be observed that MNCs (normally <18 µ m) 
and single SW480 carcinoma cells passed the mesh, whereas
cells/aggregates larger than 20 µ m were retained. The success 
of this physical process was shown by the analysis of Ki-ras
mutation. In contrast to single cells, aggregated cells were isolated
with a purity higher than 50% which enables analysis of GI at 
the DNA level. On the other hand, we frequently found relatively
high peak-integrals corresponding to the wild-type fragment in 
the spiking assays using single SW-480 cells. Nevertheless, the 
wt-integrals were within the standard deviation obtained for
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British Journal of Cancer (2000) 83(12), 1664–1673 ©2000 Cancer Research Campaign
1.0
0.8
0.6
0.4
0.2
0.0
0 20 40 60 80
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
r
e
l
a
p
s
e
-
f
r
e
e
 
s
u
r
v
i
v
a
l A
B
C
0- 1 GI (22/68)
all (71/178)
‡ 2 GI (17/29) X   vs.   Y P Value
0- 1 G1
‡ 1 G1
0- 1 G1‡ 2 G1
all
all 0.175
0.034
0.006
Months
50
40
30
20
10
0
50
40
30
20
10
0
60
0 GI 1 GI ‡ 2GI
nodal negative
0 GI 1 GI ‡ 2GI
nodal negative
P
a
t
i
e
n
t
s
 
(
%
)
P
a
t
i
e
n
t
s
 
(
%
)
100
Figure 6 (A) Actuarial relapse-free survival curves for breast cancer
patients stratified by genomic imbalances (14 parameters; see Figure 4)
detected in isolated MRCC of the blood derived from all patients receiving no
adjuvant chemotherapy (n= 178; thick line: RFS of all, unstratified patients).
Patients tested positive for genomic imbalances in isolated MRCC were
included as indicated (0–1 GI and ≥ 2 GI). Patients tested negative for GI in
MRCC were included only if the analysis was informative (heterozygous) for
DCCand evaluable (peak-integrals of the measured PCR-products) in
c-erbB-2and DCCanalyses as described in the Materials and methods
section. Numbers between brackets: failures/total number of patients in each
group. Statistical analyses are shown in the box. (B) Comparison of the
number of GI (14 parameters; see Figure 4) detected in isolated MRCC from
nodal-negative patients before adjuvant chemotherapy (n= 92/596).
(C) Comparison of the number of GI (14 parameters, see Figure 4) detected
in isolated MRCC from N0 M0 patients (n= 110; 0 GI: 24 (21.8%); 1 GI: 48
(43.6%); ≥ 2 GI: 38 (34.5%)) and the clinically diagnosed relapse during the
observation period (0 GI: 4/24 (17%), 1 GI: 15/48 (31%), ≥ 2 GI: 21/38 (55%);
0 GI vs 1 GI: P: not significant; 0 GI vs ≤ 2 GI: P= 0.003) 
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aggregated cells. The background of measured wt-integrals with
the observed differences may be explained by a passive adhes-
ion of ‘normal’ blood lymphocytes at the mesh. In contrast, wt-
integrals in spiking assays using single SW-480 cells are
somewhat higher if compared with assays using aggregated SW-
480 tumour cells. We cannot exclude that the different growing
conditions (silanized glass tubes vs. tissue flasks) will have any
effect on the expression and function of e.g. adhesion molecules.
Furthermore, single cells used in our assays had been trypsinized,
whereas aggregated cells were not treated. These different treat-
ments may lead to the slightly higher values of wt-integrals in
single cell assays. On the other hand, this assay acts as a ‘proof of
principle’ and showed clearly the possibility of size-dependent
isolation of aggregated tumour cells. The highly selective purifica-
tion of spiked aggregated tumour cells was further shown using
RT-PCR specific for the 17-1A (EGP) antigen. In whole blood and
isolated MNC, EGP-specific RT-PCR always leads to positive
results (de Graaf et al, 1997 and own observations). Contrastingly,
positive results were not found in MRCC-fractions derived from
24 healthy volunteers, showing clearly the possible applicability
of RT-PCR analyses from purified MRCC. 
The methodical evaluation indicated an extremely high dia-
gnostic specificity of MRCC detection using DNA analyses. On the
other hand, molecular detection and characterization of purified
MRCC from patients has to reflect the polyclonality of malignant
disorders (Aubele et al, 1999). Furthermore, GI in metastases and
MRCC are quite different from alterations found in the primary
tumour (Hampl et al, 1999; Offner et al, 1999). Therefore, single
parameter analyses as performed by many scientific groups, does
not describe the complexity of this disease. To overcome these
problems, specific analytical proof for the presence and characteri-
zation of MRCC was performed at the DNA level measuring up to
20 GI. This panel was necessary to increase the diagnostic sens-
itivity. Using this full panel of analyses (Figure 7), we found 71%
of all patients analysed positive for MRCC defined by at least one
GI. The detection rate of MRCC was not associated with nodal
status or grading of the primary tumour. Contrastingly, stratifica-
tion of patients by genomic characterization of MRCC had an
enormous prognostic impact. The best prognostic value within our
analytical panel was provided by GI of the DCC and c-erbB-2
genes (Figure 3). Determination of these two GI led to the clear
identification of 15.2% of the patients with worst prognosis and
26.6% of all patients encountered a favourable prognosis of RFS.
Whereas the nodal status of patients (307/353 with known nodal
status) provides prognostic information on RFS (Figure 4B; P =
0.026), evaluation of grading (Figure 4C; 265/353) did not reach
statistic significance. Contrastingly, analyses of GI (14 parameter)
in isolated MRCC (Figure 4A) showed a highly significant correla-
tion with respect to RFS (≥ 2 GI vs 0 GI; P = 0.0008). Because
informative analyses of DCC and c-erbB-2 were extremely
relevant, we stated patients as negative for MRCC (0 GI) only, if
both analyses were informative and reliable. Using a panel of 14
analyses, we increased the diagnostic sensitivity of MRCC detec-
tion defined by one or more GI found in disseminated tumour cells. 
There was only a tendentious, but not significant correlation in
RFS from patients with only one GI in MRCC compared with
MRCC negative (no detectable GI) patients. In contrast with
recently published data (Engel et al, 1999), we found a clear associ-
ation of increasing numbers of GI found in MRCC with worse
prognosis, a model also discussed earlier for primary tumours
(Harada et al, 1994). This correlation was independent from nodal
status (Figure 5) and grading (data not shown) of the patients
primary tumour. Determining possible effects derived from
chemotherapeutic treatment on MRCC in blood, we stratified
patients without adjuvant chemotherapy. Again we found remark-
able and significant correlations comparing the number of GI in
MRCC with RFS (Figure 6A). Furthermore, in nodal-negative
patients analysed before adjuvant chemotherapy (Figure 6B;
92/596), we found in 65% MRCC; 23% of these patients were pos-
itive for MRCC with ≥ 2 GI. These patients may belong to a clearly
defined high-risk group experiencing benefit from chemother-
apeutic intervention. This assumption could further be confirmed if
considering the fate of the N0M0 patients (Figure 6C). An ongoing
disease was significantly associated with increasing GI measured in
MRCC. Therefore, purification and genotyping of MRCC should
allow individualized therapeutic decisions in nodal-negative
patients, a subgroup of patients where therapeutic decisions and
prognostication of ongoing disease is extremely difficult. 
To further increase the diagnostic sensitivity and therefore,
leading to a better characterization of MRCC derived from the
Table 3 Statistical assessment of the independent prognostic value of GI 
A Logistic regression 
Responses/levels P value for H0: β = 0 
Dependent variable GI 0 or 1 / ≥ 2 
Independent variables nodal status negative/positive 0.42 
grading G1 or G2/G3 or G4 0.73 
menopausal status pre/post 0.40 
B Cox multivariate analyses of relapse-free survival 
Factor P value RHR (95% CI) 
Nodal status 0.13 1.60 0.87–2.97 
Grading 0.25 1.43 0.77–2.65 
Menopausal status 0.07 0.56 0.31–1.04 
GI in purified MRCC 0.002 1.52 1.16–1.98 
Relative hazard rate (RHR) and 95% confidence interval (CI) of multivariate analysis (final model, patients
corrected for the basic model, including nodal status, grading and menopausal status; n = 183). 1672 F Austrup et al
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blood of breast cancer patients, we re-analysed in 199/353 ran-
domly selected patients 6 additional chromosomal regions for the
presence of GI (Figure 7). Again, all healthy volunteers tested
were negative for these GI in isolated cell fractions. Therefore, we
assume a nearly 100% specificity of our analyses (data not shown).
In these 199 patients we analysed 20 chromosomal regions. Using
this panel of parameters, the detection rate of MRCC was 71% of
the patients with ≥ 1 GI in MRCC. Again, increasing numbers of
GI in MRCC were highly correlated with worse RFS (0 GI vs ≥ 4
GI: P= 0.002). 
The interesting finding of the present study concerns the indi-
vidualized prognostic impact of increasing GI in isolated MRCC
from blood of breast cancer patients. Furthermore, logistic regres-
sion and multivariate analyses (Table 3) favoured GI, independent
from nodal status, grading and menopausal status, as the best pro-
gnostic factor. Contrasting to analyses of the primary tumour,
MRCC detection and characterization enables continuous mon-
itoring of patients. 
Using this system, we identified in nearly 71% of the patients
(Figure 7, 20 parameters) MRCC with one or more GI. On the
other hand, highly statistical significance with respect to RFS was
given only if 2 or more GI were present in MRCC. The same holds
true if the patients were analysed using the reduced set of 14 para-
meters but with a lower overall detection rate of MRCC. Due to
the heterogeneity of tumours, an increase in the number of analyt-
ical parameters leads consequently to an increased sensitivity in
MRCC detection. These findings may be explained by the exist-
ence of different cancer cell clones in the blood of breast cancer
patients. We hypothesize that dissemination of cancer cells from
the primary tumour occurs in nearly all patients, leading to the
definition of cancer spread as a systemic disease. The total number
of GI accumulated within the tumour cells seemed to be crucial for
the estimation of individual risk for early recurrence of disease.
Despite the high percentage of MRCC positive patients these data
are concordant with recently published data. Soria et al (1999)
detected telomerase positive cancer cells using RT-PCR after
immunomagnetic purification of 17-1A antigen expressing MRCC
in 84% of advanced breast cancer patients (Stage IV). Brandt and
co-workers (1998) found cytokeratin positive MRCC using
immunohistochemistry in 63% of the blood samples from breast
cancer patients at different stages. Furthermore, they found
predominantly aggregated cytokeratine-positive tumour cells.
Single and clustered cells were found in 45% and 83% of the pos-
itive patients, respectively and c-erbB-2 amplification could be
detected more often in aggregated than in single tumour cells. For
these reasons, the quoted authors favoured the hypothesis of two
different, morphologically and genomically (c-erbB-2 amplifica-
tion) distinguishable MRCC subpopulations in the blood. They
hypothesize that aggregated tumour cells are a prerequisite for
metastases. Using our system, we are not only able to identify
MRCC in the blood of breast cancer patients; further characteriza-
tion of GI using multiple markers of chromosomal alterations will
give insight into tumorigeneic processes leading to metastases and
probably into tumour biological behaviour. We do not believe that
the high incidence of MRCC detection was a result of false posi-
tive findings. The isolation and detection system is extremely
sensitive and reliable for the following reasons: (1) the analysis of
GI is independent from background transcription often called ille-
gitimate transcription of tumour-specific or -associated antigens,
problems often described in RT-PCR analyses; (2) the cut-off value
of 50% relative allelic difference in determining LOH or amplifica-
tion was set extremely high; (3) there is no predominant loss of the
‘longer’ allele amplificate resulting after microsatellite PCR; (4) we
never found GI in MRCC-fractions derived from healthy volunteer
control samples, showing the specificity of the diagnostic system;
(5) applying multi-parameter analysis of GI in separated MRCC will
increase the sensitivity of the detection system.
Tumour cells in metastases do not reflect the genotype of the
matched primary tumour (Hampl et al, 1999). Therefore, we
compared GI in MRCC with alterations published for primary
tumours. Kirchweger et al (1994) described LOH of TP53in 46%
of breast cancer specimens analysed. Using our method, we identi-
fied MRCC with p53LOH in only 16% of all informative cases 
(n= 245/353) favouring the hypothesis of major genomic differ-
ences between the primary tumour and MRCC. This fact is further
substantiated by data published from Offner et al (1999) for 
p53 overexpression. Whereas Carter et al (1994) found LOH of
D11S528 in 39% of primary tumour samples investigated, MRCC
showed LOH in nearly 20% of all informative cases (n= 205/353).
These observations show clearly that disseminated cancer cells do
not reflect the genotype of the primary tumour. These differences
may be explained by the heterogeneity of primary tumours leading
to extravasation of distinct subclones and/or by additional muta-
tional events occurring in MRCC during circulation and retention
in different organs, leading eventually to sessile micrometastases
and recirculation (Aubele et al, 1999; Hampl et al, 1999). Ac-
cumulation of GI during circulation and retention of MRCC may
be a result of clonal selection altering the tumour biologic behav-
iour. On the other hand, sessile tumour cells within the primary
tumour accumulate other GI leading to distinct genomic differ-
ences comparing primary carcinomas and MRCC. 
Summarizing our data we present a new, density- and size-
dependent isolation method for the identification and characteriza-
tion of disseminated tumour cells from peripheral blood of breast
cancer patients. Isolation of large cells and aggregates leads to a
cellular fraction of MRCC with detectable GI. The detection of
disseminated tumour cells, especially the quantity and the compo-
sition of genomic imbalances correlated with the clinical outcome
of the patients. Analyses of relapse-free survival and the quantity
of GI showed the independent prognostic impact generated by
genotyping of MRCC. The major genomic differences between
primary tumours and MRCC favours the analysis of MRCC in the
blood as the real target for systemic therapy. This system enables
not only the detection and characterization of minimal residual
disease of individual patients, it seems also very useful to estimate
prognosis, progression and prediction of cancer patients leading to
a new approach in cancer management. 
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